A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
- Conditions
- Myelodysplastic Syndromes
- Registration Number
- NCT00050843
- Lead Sponsor
- Celgene Corporation
- Brief Summary
The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 220
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (38)
Scripps Cancer Center
🇺🇸La Jolla, California, United States
Comprehensive Cancer Centers of the Desert
🇺🇸Palm Springs, California, United States
Desert Hematology Oncology Medical Group INC
🇺🇸Rancho Mirage, California, United States
Whittingham Cancer Center
🇺🇸Norwalk, Connecticut, United States
VA Connecticut Healthcare System
🇺🇸West Haven, Connecticut, United States
Florida Cancer Specialists
🇺🇸Fort Myers, Florida, United States
Southeast Florida Hematology-Oncology
🇺🇸Ft. Lauderdale, Florida, United States
Northwest Medical Specialists
🇺🇸Arlington Heights, Illinois, United States
Oncology Associates
🇺🇸Cedar Rapids, Iowa, United States
Beaumont Cancer Center
🇺🇸Royal Oak, Michigan, United States
Scroll for more (28 remaining)Scripps Cancer Center🇺🇸La Jolla, California, United States